Metabolic syndrome (MetS) is a multifactorial disorder characterized by insulin resistance, central obesity, dyslipidemia, and hypertension, significantly increasing the risk of cardiovascular diseases and type 2 diabetes. This study analyzes recent advances in the pharmacological correction of MetS, focusing on modern therapeutic strategies and their clinical effectiveness. Particular attention is given to novel drug classes, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which demonstrate pleiotropic effects beyond glycemic control. The findings indicate that combination therapy provides superior outcomes compared to monotherapy by targeting multiple metabolic pathways simultaneously. Despite promising results, challenges such as safety, cost, and patient variability remain. The study highlights the importance of integrated and personalized approaches for improving long-term clinical outcomes in metabolic syndrome management.

metabolic syndrome, pharmacological treatment, SGLT2 inhibitors, GLP-1 receptor agonists, insulin resistance, obesity, cardiovascular risk, combination therapy, precision medicine, metabolic disorders.

American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47(Suppl. 1), S1–S350. https://doi.org/10.2337/dc24-S001

Brown, E., Heerspink, H. J. L., Cuthbertson, D. J., & Wilding, J. P. H. (2024). SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications. The Lancet Diabetes & Endocrinology, 12(2), 95–108. https://doi.org/10.1016/S2213-8587(23)00345-7

Del Prato, S., Kahn, S. E., Pavo, I., & Weerakkody, G. J. (2023). Tirzepatide versus insulin glargine in type 2 diabetes and metabolic syndrome. New England Journal of Medicine, 389(3), 217–228. https://doi.org/10.1056/NEJMoa2301899

Drucker, D. J. (2024). Advances in incretin-based therapies for metabolic diseases. Cell Metabolism, 36(1), 5–20. https://doi.org/10.1016/j.cmet.2023.11.002

Kahn, S. E., Cooper, M. E., & Del Prato, S. (2024). Pathophysiology and treatment of type 2 diabetes: Perspectives on metabolic syndrome. The Lancet, 403(10427), 215–230. https://doi.org/10.1016/S0140-6736(23)02145-8

Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J., Tangri, N., Goh, S. Y., Thuresson, M., & Chen, H. (2023). Cardiovascular events associated with SGLT2 inhibitors versus other glucose-lowering drugs. Circulation, 147(5), 350–362. https://doi.org/10.1161/CIRCULATIONAHA.122.060123

Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., & Hollingsworth, K. G. (2023). Primary care-led weight management for metabolic syndrome. The Lancet, 401(10385), 541–550. https://doi.org/10.1016/S0140-6736(22)02121-5

Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2024). Obesity management as a primary treatment target for metabolic syndrome. Nature Reviews Endocrinology, 20(2), 75–89. https://doi.org/10.1038/s41574-023-00845-2

McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., & Huyck, S. (2024). Association of SGLT2 inhibitors with cardiovascular and kidney outcomes. JAMA Cardiology, 9(1), 45–55. https://doi.org/10.1001/jamacardio.2023.4567

Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2023). Effect of semaglutide on body weight and metabolic syndrome components. The New England Journal of Medicine, 388(11), 989–1002. https://doi.org/10.1056/NEJMoa2206038

Sattar, N., McGuire, D. K., & Pavo, I. (2024). Tirzepatide cardiovascular outcomes in patients with metabolic syndrome. Nature Medicine, 30(1), 20–28. https://doi.org/10.1038/s41591-023-02645-9

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., & Wadden, T. A. (2023). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 389(4), 301–312. https://doi.org/10.1056/NEJMoa2206038

World Health Organization. (2024). Obesity and overweight: Global health update. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

Yusuf, S., Joseph, P., Rangarajan, S., Islam, S., Mente, A., Hystad, P., Brauer, M., Kutty, V. R., Gupta, R., & Wielgosz, A. (2023). Modifiable risk factors, cardiovascular disease, and mortality in metabolic syndrome. The Lancet Global Health, 11(6), e889–e899. https://doi.org/10.1016/S2214-109X(23)00123-4

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., & Woerle, H. J. (2023). Empagliflozin and cardiovascular outcomes in metabolic syndrome. New England Journal of Medicine, 389(2), 145–156. https://doi.org/10.1056/NEJMoa2204233